



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 47/48</b>	<b>A1</b>	(11) International Publication Number: <b>WO 95/28965</b> (43) International Publication Date: 2 November 1995 (02.11.95)
<p>(21) International Application Number: PCT/EP95/01407</p> <p>(22) International Filing Date: 13 April 1995 (13.04.95)</p> <p>(30) Priority Data: MI94A000790 22 April 1994 (22.04.94) IT</p> <p>(71) Applicant (for all designated States except US): CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): CHIESI, Paolo [IT/IT]; Via Palermo, 26 A, I-43100 Parma (IT). VENTURA, Paolo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). DEL CANALE, Maurizio [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). REDENTI, Maurizio [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). ACERBI, Daniela [IT/IT]; Via Palermo, 26 A, I-43100 Parma (IT). PASINI, Massimo [IT/IT]; Via Palermo, 26 A, I-43100 Parma (IT). SZEJTLI, Josef [HU/HU]. Cyclolab, Cyclodextrin Research and Development Laboratory, Dombóvári út 17-19, H-1117 Budapest (HU). VIKMON, Maria [HU/HU]; Cyclolab, Cyclodextrin Research and Development Laboratory, Dombóvári út 17-19, H-1117 Budapest (HU). FENYVESI, Eva [HU/HU]; Cyclolab, Cyclodextrin Research and Development Laboratory, Dombóvári út 17-19, H-1117 Budapest (HU).</p>		<p>opment Laboratory, Dombóvári út 17-19, H-1117 Budapest (HU).</p> <p>(74) Agent: BIANCHETTI, Giuseppe; Studio Consulenza Brevettuale, Via Rossini, 8, I-20122 Milano (IT).</p> <p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: HIGH SOLUBILITY MULTICOMPONENT INCLUSION COMPLEXES CONSISTING OF AN ACIDIC DRUG, A CYCLODEXTRIN AND A BASE</p> <p>(57) Abstract</p> <p>Multicomponent inclusion complexes characterized by the presence of an acidic drug, a base and a cyclodextrin are disclosed. Said complexes have a specific solubility in water.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HIGH SOLUBILITY MULTICOMPONENT INCLUSION COMPLEXES  
CONSISTING OF AN ACIDIC DRUG, A CYCLODEXTRIN AND A BASE

The invention relates to multicomponent inclusion complexes basically consisting of a drug bearing an acidic group (hereinafter defined as acidic drug), a cyclodextrin and a base.

5 In Italian Patent application n° MI93 A 000141, three-component inclusion complexes consisting of a basic-type drug, a cyclodextrin and an acid, characterized by a very high solubility in water, were described.

10 The drugs used in the formation of these complexes, in the presence of the organic or inorganic acid which acts as a counter-ion, give rise to amphiphilic structures, i.e. characterized by a strongly hydrophobic group and an hydrophilic polar  
15 head.

It is known that the molecules with such a structure have colloidal properties in aqueous solutions, i.e. they are capable of forming aggregates at suitable concentration and of lowering the surface  
20 tension of the solvent: in other words, they act as surfactants.

Among the classes of compounds which have mostly been studied from this aspect (Attwood D., Florence A.T., Surfactant Systems, their chemistry, pharmacy and  
25 biology, Chapman and Hall, UK, 1983) are the diphenylmethane derivatives and the tricyclic derivatives, some of which (terfenadine, tamoxifen, cyclobenzaprine) turned out to be excellent agents for

the formation of the multicomponent complexes.

Therefore, it has been assumed that the high, unexpected increase in the solubility of the hydrophobic guest drug and of the cyclodextrin which is observed when the multicomponent complexes are dissolved in water, is due to a reciprocal, synergistic effect of a component on the other: in other words, the cyclodextrin would increase the guest solubility by complexation, whereas the guest, once reached a concentration in solution sufficient to give aggregates and/or micells would act as a surfactant towards the cyclodextrin.

The preparation processes, which consist in removing solvent from a supersaturated solution of the components, would favour such a mutual interaction.

Measurements of the relaxation time "spin-lattice" on the proton and "spin-spin" on the carbon carried out on the multicomponent complex terfenadine-tartaric acid- $\beta$ -cyclodextrin confirmed that the drug guest is certainly aggregated in solution and therefore it is capable of acting as a surfactant.

Now it has surprisingly been observed that the aggregation also remains in the presence of cyclodextrins, contrary to what reported in literature.

It is known, in fact, that cyclodextrins generally increase the critical micellar concentration (c.m.c.) this creating conditions unfavourable to micellation [Casu B., Grenni A., Naggi A. and Torri G., In Proceedings of the Fourth International Symposium on Cyclodextrin, Eds. O. Huber and J. Szejtli., Kluwer Academic Publishers, Dordrecht, 1988, pp. 189-195;

Satake I., Ikenoue T., Takeshita T., Hayakawa K. and Maeda T., Bull. Chem. Soc. Jpn., 58, 2746-2750 (1985)].

A number of examples of formation of complexes with cyclodextrins in the presence of conventional surfactants are reported in literature [R. Palepu, J.E. Richardson, V.C. Reinsborough: Langmuir 1989, 5, 218-221; G. Nelson, I.M. Warner: Carbohydr. Res. 1989, 192, 305-312] and the formation of complexes of cyclodextrins with amphyphilic drugs was described by Takiwasa N. et al. in Colloid. Polym. Sci. 1993, 271(5) which characterized the thermodynamic properties thereof.

Up to now, however, no examples are known using the intrinsic surfactant properties of the included molecule to obtain very soluble complexes as far as both the included molecule and the cyclodextrin itself are concerned.

This principle was verified by the Applicant also for acidic drugs having a potentially amphyphilic structure.

Thus it has been found, and it is the object of the present invention, that also with acidic molecules, the simultaneous salt formation with suitable basic counter-ions and complexation with cyclodextrins, dramatically increases the aqueous solubility.

Usually, as for basic drugs addition salts with organic or inorganic acids are prepared to enhance solubility, analogously for acidic drugs salts with organic or inorganic bases are used.

The preparation of these salts, in order to increase solubility, in many cases only favours the

preparation of the pharmaceutical formulation, without involving a real advantage in terms of an enhanced absorption.

5 In fact, it often happens that the dissociation constant of the salt is higher than the pH of the medium in which the absorption takes place (mucosa, cutis or plasma) whereby even administering the salt in the absorption site the drug is found in the form of the free acid.

10 In the case of acidic drugs also the poor solubility and the subsequent reduced bioavailability can be improved by means of the complexation with cyclodextrins.

15 In the prior art a lot of examples of acidic drugs complexed with cyclodextrins with good results are described.

Now it has surprisingly been found that the formation of complexes of acidic drugs with cyclodextrins (CD) in the presence of bases in set  
20 molar ratios gives rise to the formation of complexes easily soluble in water with very high concentrations of both guest and host molecules.

The general method for the preparation of acidic drug:CD:base complexes is based on the usual principle  
25 of removing solvent from a supersaturated solution of the components, and it involves the following steps:

- a) suspension: suitable amounts of drug, cyclodextrin and base in defined stoichiometric amounts are suspended in distilled water or other suitable  
30 solvent;
- b) homogenization: the suspension is homogenized by

stirring and/or sonication until obtaining an opalescent solution;

c) filtration: the solution is filtered, with a suitable system, until obtaining a clear solution;

5 d) drying: water or solvent is removed by conventional techniques such as freeze-drying, spray-drying, drying in oven and the like.

With the same method, complexes with alfa or gamma CD, hydroxypropyl- $\beta$ CD (HPBCD), dimethyl- $\beta$ CD (DIMEB),  
10 RAMEB (Random Methylated  $\beta$ -cyclodextrin) or other cyclodextrin derivatives can be prepared to obtain, with the most soluble  $\beta$ CD derivatives, even more concentrated solutions with good stability characteristics which can give liquid pharmaceutical  
15 preparations for oral or parenteral use.

The basic component of the complexes according to the invention can be of both inorganic and organic nature.

Specific examples of bases comprise alkali or  
20 alkaline-earth hydroxides, secondary or tertiary amines, such as diethanolamine, triethanolamine, diethylamine, methylamine, tromethamine (TRIS) and the like.

By acidic drug any drug is meant having at least  
25 an acidic function such as a carboxy, sulfonic, sulfonylamino, sulfonylureic, phenol group and the like.

Examples of classes of acidic drugs comprise  
30 oxicams, hypoglycemic sulfonylureas, benzothiadiazine diuretics, barbituric acids, arylacetic and arylpropionic antiinflammatory acids.

The molar ratios of the cyclodextrin or derivative can vary from 0.5 to 10 per mole of drug, whereas the molar ratios of the basic component can vary from 0.1 to 10 moles, per mole of drug.

5       The invention is illustrated in detail by the following examples.

      The examples relates to drugs belonging to different chemical and therapeutical classes, selected as particularly significant test molecules, based on  
10       their characteristics, to exemplify the invention.

      However, the invention itself can obviously be applied to any other suitable acidic molecule.

#### EXAMPLE 1

Preparation of glibenclamide- $\beta$ CD-sodium hydroxide  
15       soluble complexes.

      20 mmoles of sodium hydroxide are dissolved in 1 litre of distilled water. This solution is added with, in sequence, 60 mmoles of  $\beta$ CD and 20 mmoles of glibenclamide. with stirring. The suspensions are  
20       homogenized by strong stirring and sonicated until obtaining slightly opalescent solutions. The solutions are filtered through a sintered glass pre-filter. The solid complexes are obtained by freeze-drying the clear solution. The X ray diffraction pattern of the product  
25       shows a completely amorphous structure.

#### EXAMPLE 2

Preparation of glibenclamide- $\beta$ CD-diethanolamine complexes.

      1 mmole of glibenclamide and 2 mmoles of  $\beta$ CD are  
30       suspended in 60 ml of distilled water. Then the suspension is added with 1 to 4 mmoles of



diethanolamine and sonicated for some minutes. The resulting clear or slightly opalescent solutions are filtered through a syntered glass pre-filter. The resulting solutions are freeze-dried.

5     EXAMPLE 3

Preparation of other glibenclamide- $\beta$ CD-organic bases complexes.

With a process analogous to the one of the above examples, the following complexes were prepared:

- 10     3a)         glibenclamide (1 mmole) - $\beta$ CD (1 mmole) -  
                  triethanolamine (2 mmoles) in a 1:1:2 ratio;  
           3b)         glibenclamide (1 mmole) - $\beta$ CD (1 mmole) -  
                  diethylamine (2 mmoles) in a 1:1:2 ratio;  
           3c)         glibenclamide (1 mmole) - $\beta$ CD (1 mmole) -  
15                 triethylamine (2 mmoles) in a 1:1:2 ratio;  
           3d-e-f)     glibenclamide- $\beta$ CD-triethanolamine (or diethy-  
                          lamine or triethylamine) in a 1:2:2 ratio;  
           3g)         glibenclamide (1 mmole) - $\beta$ CD (1 mmole) - TRIS  
                          (7 mmoles) in a 1:1:7 ratio;  
20     3h)         glibenclamide (1 mmole) - $\beta$ CD (2 mmoles) -  
                          TRIS (7 mmoles) in a 1:2:7 ratio.

EXAMPLE 4

Preparation of piroxicam-DIMEB-sodium hydroxide complexes.

- 25                 50 mmoles of piroxicam and 100 mmoles of DIMEB are  
                  suspended in 420 ml of distilled water. 50 ml of a 1N  
                  sodium hydroxide solution are added with continuous  
                  stirring. The resulting solution is filtered and the  
                  complex is separated by freeze-drying.

30     EXAMPLE 5

Preparation of piroxicam- $\gamma$ CD-inorganic bases complexes.

6 mmoles of piroxicam and 12 mmoles of CD are suspended in 100 ml of distilled water. 8 ml of a 1N sodium hydroxide (or potassium or ammonium) solution are added with stirring. The solution is neutralized until a fine precipitate of the complex is obtained (pH 8-10).

The complex is separated by filtration and dehydrated in oven at 40-50°C. With a similar process, the complex piroxicam- $\beta$ CD-sodium hydroxide in a 1:1:1 ratio was prepared.

#### EXAMPLE 6

Preparation of piroxicam-HP $\beta$ CD-NaOH complexes.

10 mmoles of piroxicam and 10 or 20 mmoles of HP $\beta$ CD (substitution degree 4.2) are suspended in 100 ml of distilled water. 10 ml of a 1N NaOH solution are added with stirring. The resulting solution is filtered and the complexes are separated by freeze-drying.

#### EXAMPLE 7

Preparation of other complexes of piroxicam with cyclodextrins and organic bases. With a process analogous to the one of example 6, the following complexes were prepared:

- piroxicam- $\beta$ CD-diethanolamine in a 1:2:1 and 1:2:2 ratio;
- piroxicam- $\gamma$ CD-diethanolamine in a 1:2:1 and 1:2:2 ratio.

#### EXAMPLE 8

Preparation of chlorotiazide-cyclodextrin-organic base complexes.

With a process analogous to the one of the above

examples, the following complexes were prepared:

- chlorothiazide-  $\gamma$ CD-lysine in a 1:1:2 and 1:2:2 ratio;
- chlorothiazide-HP $\beta$ CD-lysine in a 1:1:2 and 1:2:2 ratio;
- chlorothiazide- $\beta$ CD-lysine in a 1:1:2 and 1:2:1 ratio;
- chlorothiazide- $\beta$ CD-diethanolamine in a 1:1:2 ratio;
- chlorothiazide-HP $\beta$ CD-diethanolamine in a 1:1:1, 1:1:2, 1:2:1 and 1:2:2 ratio;
- chlorothiazide-  $\gamma$ CD-diethanolamine in a 1:1:2 and 1:2:2 ratio;
- chlorothiazide-HP $\beta$ CD-ethanolamine in a 1:2:1 and 1:2:2 ratio;
- chlorothiazide-HP $\beta$ CD-triethanolamine in a 1:1:2, 1:2:1 and 1:2:2.

The most significant solubility data of some complexes of the invention are reported in Tables 1 - 5, in which they are compared with those of the starting compounds and of other systems.

#### EXAMPLE 9

Preparation of ibuprofen/ $\beta$ CD/triethanolamine 1:1:1 complex.

With a process analogous to the one of the above examples, a complex with 0.21 g (1.0 mM) of ibuprofen, 1.1 g (1.0 mM) of  $\beta$ CD and 0.15 g (1.0 mM) of triethanolamine was prepared.

The water solubility of ibuprofen was 9 mg/ml.

#### EXAMPLE 10

Preparation of indometacin/ $\beta$ CD/triethanolamine

10

1:2:2 complex.

With a process analogous to the one of the above examples, a complex with 0.24 g (0.64 mM) of indometacin, 1.53 g (1.17 mM) of  $\beta$ CD and 0.20 g (0.64 mM) of triethanolamine was prepared.

The water solubility of indometacin was 7.2 mg/ml.

EXAMPLE 11

Preparation of furosemide/ $\beta$ CD/diethanolamine 1:2:2 complex.

With a process analogous to the one of the above examples, a complex with 0.22 g (0.64 mM) of furosemide, 1.53 g (1.17 mM) of  $\beta$ CD and 0.13 g (0.64 mM) of diethanolamine was prepared.

The water solubility of furosemide was 7.8 mg/ml.

Table 1: Equilibrium solubility, at room temperature, at different pH values, of Glibenclamide (G), its sodium salt (G-Na), and a physical mixture thereof with  $\beta$ CD (G/ $\beta$ CD) in a 1:1, 1:2, 1:3.

pH	Solubility [mg/ml]				
	G	G-Na	G/ $\beta$ CD		
			1:1	1:2	1:3
4.0	0.004				
7.39	0.0188				
7.5	0.020				
8.35					5.04
8.47				4.64	
8.53			3.49		
8.89	0.299				
9.0	0.600				
> 9.3		7.0			
9.53	0.768				

pKa of Glibenclamide: 6.8.

12

Table 2: Instant solubility, at room temperature, at various times, at different pH values, of multicomponent Glibenclamide/ $\beta$ CD/Diethanolamine (G/ $\beta$ CD/DEtOH) and Glibenclamide/ $\beta$ CD/NaOH (G/ $\beta$ CD/NaOH) complexes.

pH	time [min]	Solubility [mg/ml]				
		G/ $\beta$ CD/DEtOH		G/ $\beta$ CD/NaOH		
		1:2:3	1:2:4	1:1:1	1:2:1	1:3:1
1.4	15	0.10	0.10			
	20-30			0.10	0.10	
	40					0.110
5.38	10				0.17	
5.61	10	0.24				0.24
6.50	10	1.16				1.16
7.03	10				0.82	
7.3	15	21.5				
7.8	60				42.5	
9.1	05			33		
9.29	60		9.6			

Table 3: Glibenclamide concentrations versus time obtained by dissolution at room temperature in pH = 5 and pH = 1,4 buffer of Glibenclamide (G), a physical mixture thereof with  $\beta$ CD (G/ $\beta$ CD) and multicomponent Glibenclamide/ $\beta$ CD/NaOH) (G/ $\beta$ CD/NaOH) complexes.

pH	time [min]	Solubility [mg/ml]			
		G/ $\beta$ CD/NaOH 1:2:1	G/ $\beta$ CD/NaOH 1:3:1	G/ $\beta$ CD 1:2	G
5.0	05	0.61		< 0.01	< 0.01
	10	0.81		< 0.01	< 0.01
	20	0.36		< 0.01	< 0.01
	40	0.23		< 0.01	< 0.01
	50	0.27		< 0.01	< 0.01
1.4	05		0.110		< 0.01
	15		0.114		< 0.01
	30		0.110		< 0.01
	40		0.110		< 0.01
	50		0.080		< 0.01

14

Table 4: Equilibrium solubility (eq.) and instant solubility at various times, at room temperature, at different pH values, respectively of Piroxicam (P) and multicomponent Piroxicam/RAMEB/NaOH (P/RAMEB/NaOH) and Piroxicam/HP $\beta$ CD/NaOH (P/HP $\beta$ CD/NaOH) complexes.

5

pH	time [min]	Solubility [mg/ml]			
		P	P/RAMEB/NaOH 1:2:1	P/HP $\beta$ CD/NaOH	
				1:1:1	1:2:1
1.2	eq.	0.108			
6.0	eq.	0.076			
6.25	10		12		
7.0	eq.	0.570			
7.5	eq.	1.030			
8.6	15				45
8.9	15			75	

10

15

note: Piroxicam pKa is 6.3; the solubility of multicomponent complexes was evaluated both at a pH lower than pKa and at pH values higher than pKa.

20



Table 5: Chlorothiazide concentrations obtained by dissolution at room temperature in water of a Chlorothiazide/HPBCD physical mixture, Chlorothiazide/cosolubilizer and multicomponent Chlorothiazide/HPBCD/cosolubilizer systems.

System	molar ratio	Solubility [mg/ml]
C/HPBCD/lysine multicomponent	1:2:1	60
C/lysine physical mixture	1:1	1.25
C/HPBCD physical mixture	1:2	0.34
C/HPBCD/triethanolamine multicomponent	1:2:2	125
C/triethanolamine physical mixture	1:2	2.9
C/HPBCD physical mixture	1:2	0.34

note: Chlorothiazide has an equilibrium solubility, at room temperature, varying as a function of pH, from 0.4 to 0.7 mg/ml about, and at pKa of 6.7 and 9.5.

In Table 1 and 4 the equilibrium solubility of some drugs used for the preparation of the complexes of the invention was determined, since for the compounds as such the respective sodium salts and the physical mixture with  $\beta$ CD the maximum solubility conditions are obtained at equilibrium.

On the contrary, in the case of the complex, (as in Tables 2 and 4), the instant solubility is determined, since in most cases to define the maximum solubility of a complex, also the supersaturation solubility appearing in a set time interval (which varies depending on the complex and is indicated in the Table every time) immediately after the dissolution.

The Tables also evidence that the complexes of the

invention attain a remarkable increase in solubility, compared with the starting compounds.

This increase in solubility cannot be ascribed only to the complexation of the drug, since it also  
5 occurs at pH values at which no ionization of the cyclodextrin hydroxyls is observed.

The water solubilities of acidic drugs and of  $\beta$ -cyclodextrin in some complexes of the invention are represented in Table 6.

Table 6

Complex		guest solubility		host ( $\beta$ CD) solubility	
		in water [mg/ml]		in water [mg/ml]	
Glibenclamide/ $\beta$ CD/NaOH	1:3:1	5.04		34.7	
Ibuprofen/ $\beta$ CD/Triethanolamine	1:1:1	9.0		49.5	
Indometacin/ $\beta$ CD/Triethanolamine	1:2:2	7.2		46.0	
Furosemide/ $\beta$ CD/Diethanolamine	1:2:2	7.8		53.5	

18

From the data reported in the Table 6 the remarkable solubility enhancement of  $\beta$ -cyclodextrin may be observed.

Infact the inherent aqueous solubility of  $\beta$ -cyclodextrin is 18.5 mg/ml.

Moreover we verified whether the increase in solubility of the active ingredient of the complexes of the invention act favourably also on the respective absorption characteristics.

The product resulting from complexation of glibenclamide with  $\beta$ CD and sodium hydroxide was used for these tests. Glibenclamide is a well-known drug, widely used in the treatment of non insulin-dependent diabetes mellitus. It belongs to the sulfonylureas chemical class, which is the most important group of antidiabetics active orally.

The first pharmaceutical formulations of glibenclamide gave rise to variable and incomplete absorption. The active ingredient content of such formulations in conventional tablets was 5 mg for unitary dose.

Subsequent studies allowed to obtain a novel formulation with improved bioavailability, in which the compound is present micronized in an amount of 3.5 mg for unitary dose.

The pharmacokinetic and pharmacodynamic parameters of this novel formulation in tablets are equivalent to those of the conventional formulation.

The inventors compared the absorption rate, the bioavailability and the pharmacodynamic profile of the product obtained by complexation of glibenclamide with

βCD and sodium hydroxide (glibenclamide content 3.5 mg) with the best commercial formulation of glibenclamide (Euglucon N 3.5 mg).

EXAMPLE 12

5           The study was carried out on 6 healthy volunteers which were administered with a single dose of the compounds under test, according to a randomized cross scheme.

10           Each individual received, in the fasting state, in each of the two test period, separated by a 7 day wash-out interval, a tablet containing the complex of the invention or the reference compound (glibenclamide content of both: 3.5 mg) together with a bolus of 40 g of glucose. 30 minutes later, a second bolus of 50 g of  
15   glucose was administered. At different times and up to 12 hours after the administration of the compounds, the plasma concentrations of glibenclamide, insulin and glucose were evaluated.

20           Table 7 shows the main pharmacokinetic parameters related to glibenclamide determined on the basis of the individual plasma concentrations.

Table 7

Parameters	Reference compound (R)	Test compound (T)	p*	90% CI T/R**
Cmax (ng/mL)	164 (124;216)	289(224;371)	0.01	135-231 %
Tmax (h)	2.25 (1.0-2.5)	0.75 (0.75-2.5)	0.05	-
AUCe (ng. h/mL)	581 (454;743)	641(531;776)	N.S.	100-122 %
T1/2abs (h)	0.38 (017;0.86)	0.13 (0.08;0.23)	0.05	15-78 %

20

b) Cmax = maximum plasma concentration

a) Tmax = time of the maximum concentration

b) AUCe = area under plasma concentration-time curve extrapolated to infinite

b) T1/2abs = absorption half-life

\* = statistical significance of the difference between two formulations  
means (n.s.= not significant) (P > 0,05)

\*\* = standard confidence interval

a) median value (range)

b) geometric means ( $\pm 1SD$ ) (SD = Standard Deviation)

The results show that after the administration of tablets containing the complex of the invention, a remarkably higher absorption rate than that of the reference formulation (about 3 times) is attained, whereas bioavailability, evaluated as the extent of absorption and proved by the AUCe value, is comparable. The data also evidenced for the complex of the invention a better pharmacodynamic activity profile, since a better control of the glycemic peaks was revealed following glucose intake and higher glycemic levels far from meals.

CLAIMS

1. Multicomponent inclusion complexes containing an acidic drug, a base and a cyclodextrin characterized in that they are obtained by simultaneous salt formation and complexation.
2. Inclusion complexes according to claim 1, wherein the base is inorganic or organic.
3. Inclusion complexes according to claim 1, characterized in that cyclodextrin is a  $\alpha$ ,  $\beta$  or  $\gamma$  cyclodextrin.
4. Inclusion complexes according to claim 1, characterized in that the cyclodextrin is a  $\beta$ -cyclodextrin derivative selected from hydroxypropyl- $\beta$ -cyclodextrin, dimethyl- $\beta$ -cyclodextrin or RAMEB.
5. Inclusion complexes according to claim 1, characterized in that, compared with the drug, cyclodextrin is present in molar ratios from 0.5 to 10 and the base in molar ratios from 0.1 to 10.
6. Complexes according to any one of claims 1-5, obtained by means of any one of the techniques conventionally used in the preparation of inclusion complexes.
7. Complexes according to any one of claims 1-5, wherein the cyclodextrin concentration is higher than its inherent aqueous solubility.
8. A process for the preparation of multicomponent inclusion complexes of the preceding claims comprising the following steps:
  - a) suspension in water or other solvent of suitable quantities of drug, cyclodextrin and base;



- b) homogenization of the suspension obtained in step a) by stirring and/or sonication to obtain a clear or slightly opalescent solution;
- c) filtration of the solution obtained in step b) by using a suitable system to obtain a clear solution;
- d) drying of the solution obtained in step c).

9. Pharmaceutical compositions containing an inclusion complex of claim 1 in a therapeutically effective amount, in combination with one or more excipients.

# INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/EP 95/01407

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,94 16733 (CHIESI FARMA SPA ;CHIESI PAOLO (IT); VENTURA PAOLO (IT); PASINI MA) 4 August 1994 cited in the application see claims	1-9
X	EP,A,0 153 998 (CHIESI FARMA SPA) 11 September 1985 see claims 1,6	1,2,6,8
X	FR,A,2 624 731 (GLAXO GROUP LTD) 23 June 1989 see page 4, line 11 - line 30 see page 5, line 22 - line 35 see page 13, line 8 - page 14, line 28; claims 1,4,8	1-7,9

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

1 August 1995

Date of mailing of the international search report

21.08.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Berte, M

## INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/EP 95/01407

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9416733	04-08-94	AU-B- 5971094	15-08-94
EP-A-0153998	11-09-85	AU-B- 550007	27-02-86
		AU-A- 3892385	29-08-85
		BE-A- 900836	15-02-85
		CA-A- 1234106	15-03-88
		IE-B- 58231	11-08-93
		JP-C- 1703351	14-10-92
		JP-B- 3070705	08-11-91
		JP-A- 60208979	21-10-85
		US-A- 4603123	29-07-86
FR-A-2624731	23-06-89	AT-B- 395943	26-04-93
		AU-B- 615245	26-09-91
		AU-B- 2735688	22-06-89
		BE-A- 1001704	13-02-90
		CA-A- 1328078	29-03-94
		CH-A- 676665	28-02-91
		DE-A- 3843059	13-07-89
		GB-A- 2211737	12-07-89
		GR-A- 88100854	31-03-94
		JP-A- 2000210	05-01-90
		LU-A- 87411	07-07-89
		NL-A- 8803126	17-07-89
		SE-A- 8804607	21-12-88
		US-A- 5221695	22-06-93

---

**This Page Blank (uspto)**